ANSWER: C

Rationale:

This question embeds a pharmacokinetic mechanism — progressive UGT1A4 upregulation by rising estrogen across pregnancy — inside a clinical scenario where the presenting complaint is breakthrough seizures on an apparently unchanged regimen. The correct diagnosis is not treatment failure requiring a drug switch, but pharmacokinetically predictable subtherapeutic drug levels requiring dose adjustment. Estrogen upregulates UGT1A4, the primary enzyme responsible for lamotrigine glucuronidation, increasing lamotrigine clearance by 40–65% across the three trimesters. Without dose increases to compensate, lamotrigine plasma levels fall progressively, and a patient who was stable at 250 mg/day before pregnancy may have plasma levels 40–60% lower by 28 weeks — well below the level that previously controlled her seizures. The appropriate immediate action is to measure the current lamotrigine level, compare it to the pre-pregnancy baseline, and increase the dose to restore that baseline level. Therapeutic drug monitoring monthly during pregnancy with dose increases as needed is the standard of care. There is no indication to switch drugs in a patient who was well controlled on lamotrigine before pregnancy — the drug is not failing, the dose is insufficient for the altered pharmacokinetics.

• Option A: Option A is incorrect because switching to levetiracetam is not indicated — the breakthrough seizures are due to subtherapeutic levels from increased clearance, not to drug failure; and switching drugs in the second trimester introduces a new drug at a time when pharmacokinetic changes are ongoing, adding unnecessary complexity and risk.
• Option B: Option B is incorrect because adding valproate is contraindicated in pregnancy due to its teratogenic and neurodevelopmental risks — valproate is specifically avoided in pregnant women with epilepsy unless no other option controls seizures; it should not be added as adjunctive therapy for what is essentially a dosing problem.
• Option D: Option D is incorrect because placental estrogen does not plateau at 30 weeks and lamotrigine pharmacokinetics do not normalize automatically; clearance remains elevated throughout the third trimester and continues until delivery, requiring ongoing monitoring and dose adjustment.
• Option E: Option E is incorrect because estrogen upregulates, not inhibits, UGT1A4 — causing increased hepatic clearance and falling levels; breakthrough seizures in this context reflect subtherapeutic levels, not toxicity from accumulation.

ANSWER: A

Rationale:

This vignette presents an elderly patient in whom phenytoin's multiple pharmacological liabilities converge simultaneously. The toxicity — drowsiness, ataxia, nystagmus — at a total level of 13.5 mcg/mL is explained by hypoalbuminemia: with albumin of 2.1 g/dL, phenytoin's free fraction rises substantially above the normal 10%, and the total level drastically underestimates pharmacologically active drug exposure. Using the Sheiner-Tozer correction (measured ÷ [0.2 × albumin + 0.1]): 13.5 ÷ (0.2 × 2.1 + 0.1) = 13.5 ÷ 0.52 = approximately 26 mcg/mL corrected — well above the therapeutic range. The drug interaction burden is severe: phenytoin induces CYP2C9 (reducing warfarin efficacy, increasing stroke and thromboembolism risk), CYP3A4 (reducing atorvastatin and amlodipine levels), and P-glycoprotein. Phenytoin's nonlinear (zero-order) kinetics mean that small dose adjustments produce unpredictable and disproportionate level changes in an elderly patient with reduced hepatic reserve — safe long-term outpatient titration is particularly hazardous. Lamotrigine or levetiracetam avoids all three of these liabilities and is the guideline-recommended choice for new-onset focal epilepsy in elderly patients.

• Option B: Option B is incorrect because the toxicity is not expected CNS adaptation — it reflects supratherapeutic free drug from hypoalbuminemia; phenytoin is not guideline-recommended as first-line for new-onset focal epilepsy in elderly patients, where lamotrigine and levetiracetam are preferred.
• Option C: Option C is incorrect because the problem is not a slightly elevated total level but a substantially elevated free fraction due to protein binding changes; reducing the total level by 20% will not address the free-fraction issue and does not resolve the drug interaction burden or the nonlinear kinetics problem — the drug should be substituted, not dose-adjusted.
• Option D: Option D is incorrect because carbamazepine is not the appropriate substitute in this patient — carbamazepine is also a potent CYP3A4 and CYP2C9 inducer that would similarly reduce warfarin, atorvastatin, and amlodipine levels; it also causes hyponatremia via ADH potentiation, which is particularly dangerous in elderly patients; and its enzyme-inducing properties are not less pronounced than phenytoin's in a clinically meaningful way.
• Option E: Option E is incorrect because albumin infusions are not a standard or appropriate strategy for managing phenytoin toxicity from hypoalbuminemia in a patient with new-onset epilepsy who should simply be transitioned to a more appropriate long-term ASD; albumin infusions have their own risks, are transient in effect, and do not address the drug interaction or nonlinear kinetics problems.

ANSWER: E

Rationale:

This vignette requires applying knowledge of vigabatrin's retinal toxicity mechanism and irreversibility to a real clinical decision-making scenario. Vigabatrin irreversibly inhibits GABA transaminase (GABA-T), causing GABA accumulation in retinal cells including Müller glial cells and retinal ganglion cells, leading to progressive peripheral retinal damage. The critical clinical fact that must be communicated to the parents is that this visual field constriction is irreversible — the retinal damage does not recover after drug discontinuation, regardless of how early it is detected or how promptly the drug is stopped. The 3-month ophthalmology visit that identified this finding is exactly the monitoring protocol designed to detect toxicity as early as possible, but early detection does not translate into reversibility. The clinical decision that follows is genuinely difficult: the team must weigh confirmed, permanent vision loss against the known consequence of undertreating TSC-associated infantile spasms — an epileptic encephalopathy that causes progressive developmental regression if not controlled. Vigabatrin achieves greater than 95% spasm cessation in TSC, and no other agent approaches this efficacy in this specific subgroup. The correct response is transparent communication with the parents about the irreversibility, followed by a shared decision-making discussion about whether to continue, reduce, or discontinue vigabatrin given the seizure control status and the degree of visual field loss.

• Option A: Option A is incorrect because vigabatrin's visual field constriction is irreversible — stopping the drug does not allow recovery, and the premise that discontinuation within 6 months prevents permanent damage is pharmacologically false; the damage is caused by the irreversible enzyme inhibition and its retinal accumulation effects, not by a reversible process.
• Option B: Option B is incorrect because while infant visual field testing has technical challenges, it is not so unreliable as to dismiss a bilateral finding on a formally conducted 3-month monitoring visit; vigabatrin's ophthalmologic monitoring protocol using age-appropriate techniques is specifically designed for this purpose and clinically validated.
• Option C: Option C is incorrect because sodium channel blockers — including all drugs in that class — are not the next step in TSC infantile spasms management; sodium channel blockers do not have evidence in TSC infantile spasms, and their use is unrelated to vigabatrin's visual toxicity pathway.
• Option D: Option D is incorrect because peripheral visual field constriction from vigabatrin is not clinically insignificant — it represents permanent structural retinal damage that may worsen with continued exposure; the claim that it remains stable without progression is not supported and underestimates the seriousness of the finding.

ANSWER: B

Rationale:

This vignette requires recognizing that reproductive counseling for valproate is not deferred until a patient plans pregnancy — it must occur before sexual activity begins, because unintended pregnancy is common and because valproate exposure during the first weeks of embryogenesis (when neural tube closure occurs) causes irreversible harm before many pregnancies are even confirmed. Four elements must be addressed at this visit. First, valproate's teratogenic profile: approximately 10% MCM rate at standard doses plus irreversible neurodevelopmental harm (6–9 IQ point reduction, increased autism and ADHD) that folic acid cannot prevent. Second, the drug transition: a supervised switch to lamotrigine or levetiracetam, planned during a stable period well before sexual activity becomes a possibility, is strongly preferred; this requires honest discussion that efficacy for the myoclonic component may be somewhat reduced, and that lamotrigine carries a risk of paradoxically worsening myoclonus in some JME patients. Third, contraception: effective contraception is essential if valproate is continued in the interim while the transition is being planned and executed. Fourth, folic acid limitation: 5 mg/day folic acid should be prescribed but the patient must understand it does not prevent the neurodevelopmental harm.

• Option A: Option A is incorrect because deferring counseling until the patient has an active plan to conceive is a dangerous strategy — unintended pregnancy is common in adolescents, and the critical embryological harm from valproate occurs weeks before pregnancy is recognized; reproductive risk counseling must occur now.
• Option C: Option C is incorrect because carbamazepine is not safe in pregnancy — it has an MCM rate of approximately 5% including specific neural tube defect risk; and carbamazepine does not control JME effectively, as it can worsen myoclonic and absence seizures in generalized epilepsy syndromes.
• Option D: Option D is incorrect because folic acid does not adequately protect any future pregnancy from valproate's neurodevelopmental harm — the NEAD study demonstrated that the IQ reduction and autism risk are not folate-dependent and are not prevented by supplementation at any dose; presenting folic acid as adequate protection misrepresents the risk and harms the patient's ability to make informed decisions.
• Option E: Option E is incorrect because ethosuximide does not control all three JME seizure types — its efficacy is restricted to absence seizures through T-type calcium channel blockade; it has no meaningful activity against myoclonic jerks or generalized tonic-clonic seizures, which are central features of JME.

ANSWER: D

Rationale:

This vignette requires applying the organ-impairment drug selection framework to a specific patient with documented Child-Pugh B cirrhosis. Valproate is contraindicated in significant hepatic disease for two compounding reasons: it undergoes extensive hepatic metabolism through mitochondrial beta-oxidation and glucuronidation, so its clearance falls substantially with liver failure causing accumulation; and it is directly hepatotoxic through mitochondrial dysfunction, adding intrinsic harm to already-compromised hepatocytes. Using valproate in Child-Pugh B or C disease carries a real risk of precipitating acute-on-chronic liver failure. Phenytoin is also problematic in this patient: hepatic failure reduces its CYP2C9-mediated clearance substantially, and its nonlinear (Michaelis-Menten) kinetics mean that small clearance reductions produce disproportionately large rises in plasma concentration — already dangerous in a patient where the hepatic reserve to handle accumulation is severely limited. Additionally, the hypoalbuminemia common in cirrhosis elevates phenytoin's free fraction, requiring free-level monitoring and making safe outpatient management particularly challenging. Levetiracetam avoids both problems: its elimination is approximately 66% renal and it does not undergo significant CYP-mediated hepatic metabolism, so hepatic dysfunction has minimal effect on its clearance. Dose adjustment in this patient is driven by renal function (CrCl-based), which can be measured directly, and it has no pharmacokinetic drug interactions.

• Option A: Option A is incorrect because valproate is contraindicated in significant hepatic disease — autoinhibition of its own metabolism is not a protective mechanism and does not prevent drug accumulation or hepatotoxicity in a patient with already-impaired hepatic function.
• Option B: Option B is incorrect because phenytoin's nonlinear kinetics are not beneficial in hepatic impairment — saturable metabolism means that any reduction in enzyme capacity from liver disease causes unpredictable, disproportionate level rises; this is a risk, not an advantage; and phenytoin's low volume of distribution statement does not accurately characterize its pharmacokinetics.
• Option C: Option C is incorrect because epoxide hydrolase activity is not upregulated in cirrhosis in a way that improves carbamazepine's therapeutic window; carbamazepine undergoes extensive hepatic CYP3A4 metabolism and requires caution in hepatic impairment, and its enzyme-inducing properties add drug interaction complexity.
• Option E: Option E is incorrect because while gabapentin's complete renal elimination is correct and makes it independent of liver function, gabapentin is not the preferred first-line ASD for new-onset focal epilepsy in this clinical context — it lacks parenteral formulation for acute use, and levetiracetam's combination of renal elimination, IV availability, broad spectrum, and zero drug interactions makes it the more appropriate choice for this patient; additionally, gabapentin does require dose adjustment in renal impairment, which should be evaluated in this patient with cirrhosis who may have concurrent renal dysfunction.

ANSWER: C

Rationale:

Childhood absence epilepsy is a self-limited epilepsy syndrome in the majority of affected children — most achieve spontaneous remission before or during adolescence, allowing ASD discontinuation in a large proportion of patients. The combination of 2 years of seizure freedom and EEG normalization in this 7-year-old boy provides appropriate grounds for attempting a supervised gradual taper of ethosuximide. Current practice supports offering a discontinuation trial after 2–3 years of seizure freedom in CAE, with the explicit understanding that recurrence is possible — most relapses occur during or shortly after the taper period. Counseling should cover: the likelihood of successful discontinuation given the favorable syndrome prognosis, the risk and management of recurrence, the need to restrict driving and other seizure-sensitive activities during the taper (though at age 7 driving is not yet relevant, the principle applies to activities such as swimming unsupervised, cycling near traffic), and a plan for restarting medication promptly if seizures recur. This approach contrasts sharply with JME, where spontaneous remission is uncommon and lifelong treatment is the norm — the prognosis distinction between CAE and JME is a core clinical concept.

• Option A: Option A is incorrect because CAE does not carry a 40–60% risk of evolving into JME — this overstates the transition risk substantially; while some children with apparent CAE are later reclassified as having JME, the majority of correctly diagnosed CAE remits without evolving; and ethosuximide does not prevent the transition to JME even if it occurs.
• Option B: Option B is incorrect because immediate discontinuation rather than a supervised gradual taper is not the standard approach — a gradual taper over weeks to months is preferred to minimize breakthrough seizure risk during the transition off medication; the threshold of 2 years of seizure freedom supports attempting discontinuation but does not mandate abrupt cessation.
• Option D: Option D is incorrect because CAE does remit spontaneously in the majority of children — this is one of its defining characteristics as a self-limited syndrome; the claim that discontinuation universally results in relapse within 3 months misrepresents the natural history of a syndrome where most patients successfully discontinue treatment.
• Option E: Option E is incorrect because there is no requirement to bridge with valproate before ethosuximide taper, and status epilepticus does not commonly result from ethosuximide discontinuation in CAE; this option introduces an unnecessary and potentially harmful additional medication into a straightforward discontinuation scenario.

ANSWER: A

Rationale:

The clinical and laboratory picture — euvolemic hyponatremia, low serum osmolality, inappropriately concentrated urine (490 mOsm/kg), elevated urine sodium (48 mEq/L), and no volume depletion — is the classic pattern of SIADH. Carbamazepine causes this pattern by potentiating the action of antidiuretic hormone on V2 receptors in renal collecting duct cells, enhancing aquaporin-2-mediated water reabsorption. Water is retained without sodium retention, diluting the plasma sodium. Elderly patients are particularly vulnerable because age-related reductions in renal free-water excretion capacity limit the compensatory response. Immediate management follows standard SIADH principles: fluid restriction to allow gradual sodium correction, with careful attention to the rate of correction — too rapid correction of chronic hyponatremia risks osmotic demyelination syndrome. The carbamazepine should be discontinued as the precipitating cause. Long-term, the patient requires an effective ASD for her focal epilepsy that does not cause SIADH — lamotrigine and levetiracetam are both appropriate alternatives that lack the ADH-potentiating mechanism.

• Option B: Option B is incorrect because carbamazepine does not cause adrenal suppression or reduce aldosterone secretion; this is a sodium-wasting mechanism that would produce hypovolemic hyponatremia with volume depletion, which is absent here; and hydrocortisone replacement is not indicated.
• Option C: Option C is incorrect because while carbamazepine does induce CYP3A4, the mechanism of hyponatremia is not aldosterone catabolism — it is direct ADH potentiation at the renal tubule; fludrocortisone would not address the underlying mechanism and is not the appropriate management.
• Option D: Option D is incorrect because carbamazepine does not cause nephrogenic diabetes insipidus — the opposite is true; it causes inappropriate water retention, not water wasting; and desmopressin would worsen the hyponatremia by further enhancing water retention in a patient whose problem is already too much ADH action.
• Option E: Option E is incorrect because carbamazepine does not directly inhibit aquaporin-2 channels — it enhances their insertion through ADH potentiation; adding a vasopressin receptor antagonist (vaptan) while continuing carbamazepine would treat the symptom while leaving the causative drug in place, which is not the appropriate long-term strategy when an effective alternative ASD is available.

ANSWER: E

Rationale:

This question requires distinguishing between two separate reasons to evaluate phenobarbital in Dravet syndrome, and then identifying the correct adjunctive options. First, the mechanism distinction: phenobarbital is not a sodium channel blocker — it acts at the barbiturate-binding site on the GABA-A receptor, enhancing chloride influx by prolonging channel open time. It does not block Nav1.1 channels and therefore does not carry the specific contraindication that applies to carbamazepine, phenytoin, lamotrigine, and oxcarbazepine in Dravet syndrome. The resident's reasoning about GABAergic mechanism is not entirely wrong in principle. However, the second issue is critical: phenobarbital is a potent inducer of CYP3A4, CYP2C9, and other hepatic enzymes. Adding it to a regimen of valproate and clobazam would substantially accelerate the metabolism of both drugs, reducing their plasma levels and potentially eliminating the seizure control that the existing regimen provides. This pharmacokinetic interaction — not a Dravet-specific mechanism — is the primary reason phenobarbital is problematic in this context. The correct adjunctive options for Dravet syndrome on a valproate-clobazam backbone are stiripentol (FDA-approved in the U.S. for Dravet syndrome as adjunct to valproate and clobazam), cannabidiol (Epidiolex, FDA-approved for Dravet), and fenfluramine (Fintepla, FDA-approved for Dravet syndrome).

• Option A: Option A is incorrect because while phenobarbital does not block Nav1.1 channels, it is not an appropriate adjunctive choice due to its enzyme-inducing interaction with the existing regimen — the pharmacokinetic impact on valproate and clobazam levels is clinically significant and is not addressed by the reasoning presented.
• Option B: Option B is incorrect because stiripentol is not contraindicated in infants under 12 months as a categorical rule — its approved use covers the Dravet population including young infants; and the statement that no adjunctive option is available is false given the approved alternatives.
• Option C: Option C is incorrect because phenobarbital is not contraindicated by the same Nav1.1 mechanism as carbamazepine — phenobarbital is a GABA-A modulator, not a sodium channel blocker; and stiripentol is approved in the United States, having received FDA approval for Dravet syndrome.
• Option D: Option D is incorrect because phenobarbital does not worsen the Nav1.1 deficit through a delayed epigenetic mechanism — this is a fabricated pharmacological rationale; a 4-week bridge strategy without pharmacological basis is not a standard practice and does not address the enzyme induction problem.

ANSWER: B

Rationale:

This question requires applying the pharmacokinetic principle of dialytic drug removal to a specific clinical presentation — a temporal pattern of seizures that correlates precisely with dialysis sessions. Levetiracetam has less than 10% protein binding, making it freely available for removal across hemodialysis membranes by diffusion and convection. During a 3–4 hour hemodialysis session, a clinically significant amount of levetiracetam is removed from the plasma. If the supplemental dose is administered after the session — as in this patient's current regimen — there is a window during the session itself when levetiracetam levels are falling progressively as the drug is dialyzed out, potentially reaching subtherapeutic concentrations by the second hour of the session. This explains the temporal pattern: seizures occurring approximately 2 hours into the dialysis session, when levels have fallen sufficiently to allow breakthrough activity. The correct management is to shift the supplemental dose to before or at the start of dialysis so that levels are maintained throughout the session, rather than restored only after it ends. Alternatively, the post-dialysis supplemental dose can be increased if pre-dialysis dosing is impractical.

• Option A: Option A is incorrect because while osmotic shifts during dialysis can affect neurological status, the specific temporal pattern — seizures consistently occurring 2 hours into the session — strongly implicates a drug-level explanation rather than a non-specific osmotic seizure threshold reduction; the seizures are focal and pharmacologically predictable, not osmotic.
• Option C: Option C is incorrect because the pattern is the opposite of toxicity — the seizures occur during dialysis when levels are falling, not between sessions when levels might accumulate; levetiracetam toxicity in dialysis patients would be expected between sessions on a high dose, not during dialysis sessions when the drug is being actively removed.
• Option D: Option D is incorrect because carbamazepine is not part of this patient's regimen and does not interact with dialysis membranes to release metabolites; this option introduces a pharmacologically fabricated explanation that has no basis in the clinical scenario.
• Option E: Option E is incorrect because ucb L057, levetiracetam's primary metabolite, is pharmacologically inactive and does not antagonize SV2A binding; the mechanism described is fabricated, and the temporal pattern of intra-dialysis seizures is more parsimoniously explained by drug removal during the session.

ANSWER: C

Rationale:

This vignette illustrates the lamotrigine-JME myoclonus paradox in a real clinical scenario — a patient whose myoclonic component worsens specifically after a lamotrigine dose increase, with a clear temporal relationship that implicates the dose change rather than disease progression. In JME, lamotrigine's sodium channel blocking mechanism — which is effective against generalized tonic-clonic seizures — can paradoxically aggravate the myoclonic component in some patients, particularly at higher doses. This appears to reflect the different role of sodium channel modulation in the thalamocortical circuits generating myoclonic bursts versus those generating tonic-clonic seizures; the myoclonic circuits may respond to increased sodium channel blockade with altered firing patterns that worsen rather than suppress the myoclonus. The correct clinical response is to reduce the lamotrigine dose back to the level at which myoclonus was more tolerable, accepting partial myoclonic control as the therapeutic tradeoff for maintaining the sodium channel blocking efficacy against tonic-clonic seizures. An alternative approach is to add levetiracetam as adjunctive therapy specifically targeting the myoclonic component, while maintaining lamotrigine for tonic-clonic seizure control. The patient should be counseled that this paradox is a recognized feature of lamotrigine in JME and does not represent treatment failure — it represents the inherent limitation of using a sodium channel blocker in a syndrome where the myoclonic circuits respond differently to this mechanism.

• Option A: Option A is incorrect because this is not lamotrigine toxicity — the symptom is worsening myoclonus, not the typical signs of lamotrigine toxicity (diplopia, ataxia, dizziness, nausea); and reducing to 100 mg/day without a pharmacological basis for that specific dose is not the appropriate response to a recognized paradoxical effect.
• Option B: Option B is incorrect because lamotrigine does not have a pharmacologically active N2-glucuronide metabolite; lamotrigine-2-N-glucuronide is the primary metabolite and it is pharmacologically inactive; and competitive GABA-A antagonism by a lamotrigine metabolite is not an established mechanism.
• Option D: Option D is incorrect because the temporal correlation between the dose increase and myoclonus worsening — 2 weeks after a specific dose change — makes disease progression an implausible explanation; JME does not naturally worsen in this stepwise dose-correlated manner; and adding valproate to a woman of reproductive potential is not appropriate without acknowledging the teratogenicity discussion that would need to accompany that decision.
• Option E: Option E is incorrect because lamotrigine does not undergo significant autoinduction of its own CYP metabolism; lamotrigine is metabolized by UGT1A4 glucuronidation, not CYP3A4, and does not autoinduct this pathway; the mechanism described is pharmacologically inaccurate.

ANSWER: D

Rationale:

This question asks the student to apply knowledge of rufinamide's specific seizure-type evidence in LGS and the felbamate risk-benefit calculus to a concrete patient scenario. Rufinamide's evidence in LGS is concentrated in tonic and atonic seizures — specifically the drop attacks that are the most disabling and injury-causing feature of LGS, as demonstrated in this child by two fractures in 3 months. Rufinamide's mechanism involves modulation of sodium channel inactivation, prolonging the inactive state and reducing high-frequency neuronal discharge. Its adjunctive efficacy for drop attacks makes it a rational choice when drop attacks are the dominant clinical problem, as they are here. Felbamate does have genuine, well-established efficacy in LGS — it is not avoided because it lacks evidence. It is avoided because of its black box warnings for aplastic anemia and hepatic failure, both of which are potentially fatal idiosyncratic toxicities that have no predictive biomarker and cannot be prevented by monitoring alone. In a 5-year-old who may require anti-seizure treatment for decades, the cumulative risk exposure to these toxicities across a lifetime of treatment shifts the risk-benefit balance against felbamate when a safer alternative with LGS evidence is available. This is a textbook example of appropriate hierarchical prescribing: evidence alone does not determine drug choice — the risk profile relative to alternatives is equally important.

• Option A: Option A is incorrect because rufinamide's specific evidence in LGS is for tonic and atonic seizures — drop attacks — not atypical absence seizures; and felbamate is not restricted to adults over 18 with LGS; it has been used in pediatric LGS patients, and age is not the reason it was not chosen.
• Option B: Option B is incorrect because rufinamide does not have equal evidence across all LGS seizure types through combined sodium channel and GABA-A modulation — GABA-A modulation is not rufinamide's established mechanism; and QTc prolongation is not felbamate's black box toxicity — the warnings are for aplastic anemia and hepatic failure, not cardiac effects.
• Option C: Option C is incorrect because rufinamide's mechanism is not specifically targeted to brainstem reticular formation circuits in children under 6; and felbamate's efficacy is not restricted to adults with post-traumatic LGS — it has evidence in pediatric LGS of various etiologies, and the reason it was avoided is its toxicity profile, not an indication restriction.
• Option E: Option E is incorrect because rufinamide does undergo hepatic metabolism and is not entirely non-hepatically processed; and felbamate is not a potent CYP3A4 inhibitor — the interaction concern with felbamate is its mixed inducing and inhibiting effects on various CYP enzymes, not a simple CYP3A4 inhibition that doubles valproate and clobazam levels.